With respect to clinical relevance, a recent study indicated that CXCL8 neutralizing antibodies abrogated the ability of paclitaxel and gemcitabine to elevate CSC levels in breast cancer (tumor spheroids and ALDH-expressing cells). This evidence concerns the gene CXCL8 and neoplasm.